Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Aeterna Zentaris (NASDAQ: AEZS) announced that Dr. Klaus Paulini, CEO, will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami and virtually. Following his presentation, management will be available for virtual one-on-one meetings with registered investors. A video webcast will be accessible for viewing starting May 24, 2022, at 7:00 AM ET for event registrants, and will remain available for 90 days. Aeterna is a specialty biopharma focusing on unmet medical needs, with products like macimorelin for diagnosing growth hormone deficiencies.

TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.

A video webcast of the presentation will be accessible for viewing on-demand beginning on Tuesday, May 24, 2022, at 7:00 AM ET for those registered for the event and will be available on the Events page in the Investors section of the Company’s website (zentaris.com). The webcast replay will be archived for 90 days following the event.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen^™; Ghryvelin^®), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need, in collaboration with Novo Nordisk.

Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing pre-clinical pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease). Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2 (COVID-19) and Chlamydia trachomatis.

For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

Investor Contact:

Jenene Thomas
JTC Team
T (US): +1 (833) 475-8247
E: aezs@jtcir.com

FAQ

What is the date of the H.C. Wainwright Global Investment Conference for Aeterna Zentaris (AEZS)?

The conference is scheduled from May 23-26, 2022.

Who will present for Aeterna Zentaris (AEZS) at the conference?

Dr. Klaus Paulini, CEO of Aeterna Zentaris, will present at the conference.

How can I access the video webcast of Aeterna Zentaris' presentation?

The video webcast will be available for viewing starting May 24, 2022, at 7:00 AM ET on the conference website.

What is the lead product of Aeterna Zentaris (AEZS)?

The lead product is macimorelin, approved for diagnosing adult growth hormone deficiency.

What are the therapeutic areas of focus for Aeterna Zentaris (AEZS)?

Aeterna focuses on unmet medical needs including growth hormone deficiencies and various serious neurological conditions.